Not for human consumption

Thymosin Alpha-1 Peptide (Thymalfasin) 10mg Vial | Research Grade

Thymosin Alpha-1 research peptide: ≥99% HPLC-verified purity, manufactured in LiveWell’s own Dallas cGMP facility. Thymosin Alpha-1 (thymalfasin) is a 28-amino-acid acetylated thymic peptide with one of the deepest clinical literatures of any research peptide: as Zadaxin it is approved in more than 30 countries, with randomized trial data in hepatitis B and sepsis. LiveWell already offers the tablet form: this is the 10 mg lyophilized vial. Supplied as a 10 mg lyophilized vial for in-vitro laboratory research use only.

Coming soon: pre-orders are open now. The first production batch is in the manufacturing and QC queue. Expected ship date: to be announced. Pre-orders ship in the order received once the batch clears third-party testing and the COA is published. Your card is charged at checkout and you can cancel any time before shipment for a full refund.

CAS Number: 62304-98-7 · Also known as: thymalfasin, Ta1, Zadaxin
Vial size: 10 mg lyophilized powder
Class: Thymic immunomodulator peptide, TLR2/TLR9 signaling in dendritic cells and monocytes
Purity: ≥99% HPLC, third-party tested, COA published on release
Shipping: USA same-day once released (orders before 2pm CT, Mon to Fri) · free over $200

Related: Thymosin Alpha-1 Tablets · TB-500 · KPV

For laboratory research use only. Not for human or animal consumption. Full details ↓

$ 89.99

Available on backorder

⚠️ Strictly for laboratory research use only. Not for human or animal consumption.

Quantity	Price	Discount
3-5	$ 80.99	10%
6-9	$ 76.49	15%
10+	$ 71.99	20%

Available on backorder

Add $ 200.00 to cart and get free shipping!

Description

Thymosin Alpha-1: Thymic Immunomodulator for Research Use

Thymosin Alpha-1 (thymalfasin) is a 28-amino-acid, N-terminally acetylated peptide derived from prothymosin alpha, first isolated from thymic tissue. In published immunology it signals through Toll-like receptors TLR2 and TLR9 on dendritic cells and monocytes, promoting T-cell maturation, Th1 polarization with interferon gamma and IL-2, MHC class I upregulation and enhanced NK cytotoxicity. As the drug thymalfasin (Zadaxin), it is approved in more than 30 countries, mostly for chronic hepatitis B, which gives researchers an unusually large randomized clinical dataset, including the 361-patient ETASS sepsis trial and a 2025 meta-analysis of 11 RCTs. LiveWell supplies it as a 10 mg lyophilized vial strictly for in-vitro laboratory research use only.

Chemical Information

Name: Thymosin Alpha-1 (thymalfasin, Ta1)
CAS Number: 62304-98-7
Type: N-terminally acetylated thymic peptide (research grade)
Length: 28 amino acids
Molecular weight: approximately 3108 g/mol
Mechanism: TLR2/TLR9 signaling in dendritic cells and monocytes; Th1 polarization, MHC class I upregulation, NK enhancement in published work
Vial size: 10 mg lyophilized powder
Purity: ≥99% (HPLC, third-party tested)

Why Researchers Study Thymosin Alpha-1

1. Innate-adaptive bridge pharmacology. Thymosin Alpha-1 acts on TLRs of the innate system while its downstream effects are adaptive (T-cell maturation, Th1 cytokines), making it a model compound for the innate-adaptive interface.

2. A real clinical evidence base. The ETASS sepsis RCT (361 patients) and a 2025 meta-analysis of 11 randomized trials (1,927 patients) give researchers hard numbers, positive and equivocal, that few research peptides can match.

3. Immuno-oncology re-examination. The 2023 Int Immunopharmacol review repositions Ta1 in the checkpoint-inhibitor era, driving a new wave of combination research.

4. Comparative thymic peptide research. Ta1 (immune signaling) is studied next to TB-500 / Thymosin Beta-4 (actin-binding, tissue repair), two thymosins with entirely different mechanisms despite the shared name.

Published Clinical Literature (Research Reference)

For context only. These are results from the thymalfasin clinical program and academic laboratories. These are results cited from peer-reviewed sources; they are not claims about LiveWell’s research-grade material.

Hepatitis B combination RCT (J Gastroenterol Hepatol, 2008): Ta1 1.6 mg twice weekly plus lamivudine gave 26.5% versus 6.1% HBeAg seroconversion at 24 weeks (p = 0.024).
ETASS sepsis RCT (Crit Care, 2013): 361 patients; 28-day mortality 26.0% with Ta1 versus 35.0% control (RR 0.74, 95% CI 0.54 to 1.02) with greater monocyte HLA-DR recovery.
Historical review (Expert Opin Biol Ther, 2015): three decades of thymalfasin in infectious disease.
Immuno-oncology review (Int Immunopharmacol, 2023): re-examines Ta1 mechanisms for the checkpoint era.
Sepsis meta-analysis (Front Cell Infect Microbiol, 2025): 11 RCTs, 1,927 patients; OR 0.73 (95% CI 0.59 to 0.90) for 28-day mortality, non-significant in the high-quality subgroup.
Regulatory: approved as thymalfasin (Zadaxin) in more than 30 countries including China and Italy, chiefly for chronic hepatitis B; not FDA-approved in the US (orphan designations only).

Storage & Handling

Store lyophilized vials refrigerated at 2 to 8°C, protected from light and heat
Reconstitute with bacteriostatic water; reconstituted material has a shorter storage window
Follow your laboratory’s standard peptide handling protocol

⚠️ Disclaimer: Thymosin Alpha-1 research peptide is intended strictly for laboratory research and in-vitro use only. It is not a drug, food, cosmetic, or dietary supplement. This product has not been evaluated or approved by the FDA and is not for human or veterinary use. No therapeutic, weight-management or metabolic-health claims are made or implied.

Regulatory status: Thymalfasin (Thymosin Alpha-1) is approved in more than 30 countries, mostly for chronic hepatitis B, but is not approved by the FDA in the United States, where it holds orphan-drug designations only. The research-grade material sold by LiveWell is not a drug product: it is not manufactured, compounded, or approved for pharmaceutical use, and is strictly for in-vitro laboratory research. Nothing on this page constitutes medical advice.

Thymosin Alpha-1 research reference: View the ETASS sepsis trial on PubMed

Pre-Order Thymosin Alpha-1 Research Peptide: cGMP Manufactured in Dallas, TX

Qualified researchers can pre-order Thymosin Alpha-1 directly from the manufacturer. LiveWell Peptides produces research-grade Thymosin Alpha-1 in our cGMP facility in Dallas, Texas. Every vial is third-party tested to verify ≥99% HPLC purity, amino acid identity by mass spectrometry, and endotoxin limits by LAL testing, and the batch COA is published on our COA page on the day of release. Pre-orders ship in the order received (expected ship date: to be announced); once released, US orders placed before 2pm CT (Mon to Fri) ship same-day in cold-chain packaging, with free domestic shipping over $200. International shipping is available.

Why Researchers Source Thymosin Alpha-1 from LiveWell

Documentation, not claims. Every batch ships with a verified COA confirming identity and purity, published on our COA page rather than supplied only on request.

Four-point analytical testing. HPLC for purity, mass spectrometry for amino acid identity, and LAL testing for endotoxins, with independent third-party verification on top of in-house quality control.

US manufacturing and cold-chain logistics. Orders ship from our Dallas, Texas facility, with international shipping to Colombia, Mexico, Brazil, Argentina, Chile and Peru.

Related research compounds

Thymosin Alpha-1 500mcg tablets · TB-500 (Thymosin Beta-4 fragment) · KPV (alpha-MSH fragment) · Glutathione · Bacteriostatic Water · Certificates of Analysis

Research literature

Selected peer-reviewed sources for research reference:

Chien RN et al. (2004). Thymalfasin for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther. PMID: 15482167
Lee HW et al. (2008). Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B. J Gastroenterol Hepatol. PMID: 18410608
Wu J et al. (2013). The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. PMID: 23327199
Camerini R et al. (2015). Historical review of thymosin alpha 1 in infectious diseases. Expert Opin Biol Ther. PMID: 26098768
Mao L et al. (2023). Thymosin alpha 1 – Reimagine its broader applications in the immuno-oncology era. Int Immunopharmacol. PMID: 36871535
Gu B et al. (2025). Efficacy of thymosin alpha 1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. PMID: 40969554

References are provided for research reference only. Inclusion of literature does not constitute a recommendation, endorsement, or claim for any specific use of LiveWell Peptides products. Products are sold for laboratory and research use only and are not intended for human consumption, injection, topical application, or any other administration to the human body.

Frequently Asked Questions

What is Thymosin Alpha-1?

Thymosin Alpha-1 (thymalfasin, CAS 62304-98-7) is a 28-amino-acid acetylated thymic peptide that signals through TLR2 and TLR9, promoting T-cell maturation and Th1 polarization in published immunology. We supply it as a 10 mg lyophilized vial strictly for in-vitro laboratory research.

Is Thymosin Alpha-1 approved anywhere?

Yes. As thymalfasin (Zadaxin) it is approved in more than 30 countries, including China and Italy, chiefly for chronic hepatitis B. It is not FDA-approved in the United States, where it holds orphan-drug designations only.

What is the difference between this vial and your Thymosin Alpha-1 tablets?

Same peptide, different format. The tablets carry 500 mcg per tablet; this is a 10 mg lyophilized vial for laboratories that reconstitute their own solutions.

How does Thymosin Alpha-1 differ from TB-500?

Despite the shared thymosin name they are unrelated mechanisms. Ta1 is an immune-signaling peptide acting on Toll-like receptors; TB-500 is a fragment of Thymosin Beta-4, an actin-binding protein studied in tissue repair.

What did the sepsis trials report?

The 361-patient ETASS trial reported 28-day mortality of 26.0% with Ta1 versus 35.0% control, and a 2025 meta-analysis of 11 RCTs found OR 0.73 for 28-day mortality, though the high-quality subgroup was non-significant. Published findings cited for research reference only.

What purity is LiveWell Thymosin Alpha-1, and is a COA included?

Every batch is third-party tested at ≥99% purity by HPLC, with mass spectrometry identity confirmation and LAL endotoxin testing. The batch Certificate of Analysis is published on our COA page the day the pre-order batch is released.

How should Thymosin Alpha-1 be stored and reconstituted?

Store the lyophilized vial refrigerated at 2 to 8°C, protected from light and heat. Reconstitute with bacteriostatic water; reconstituted material has a considerably shorter storage window.

How do pre-orders work, and when will it ship?

Pre-orders are charged at checkout and ship in the order received once the first batch clears third-party testing and the COA is published. You will receive tracking the day it ships. If you change your mind before shipment, contact us for a full refund.

Is Thymosin Alpha-1 a drug or supplement in the United States?

No. In the United States thymalfasin is not FDA-approved. The research-grade material sold by LiveWell is not a drug product, dietary supplement, food or cosmetic, and it is not intended for human or animal consumption.

Péptidos de investigación disponibles con envío internacional. Timosina alfa-1 de grado de investigación fabricada en instalaciones cGMP en Dallas, Texas. Certificado de análisis incluido con cada lote. Solo para uso en investigación.

Research Use Only Disclaimer: This product is sold strictly for in vitro laboratory research. NOT for human or animal consumption. LiveWell Peptides makes no medical claims.